Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.71 |
| ▸ | JAK3 | P52333 | 2/20 | 0.71 |
| ▸ | NTRK1 | P04629 | 16/20 | 0.68 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132228 | 1.00 | JAK2 (0.71) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL2568030 | 0.92 | JAK2 (0.70) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL2568031 | 0.92 | JAK2 (0.70) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL2566300 | 0.85 | JAK2 (0.74) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL2566297 | 0.85 | JAK2 (0.74) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL5027420 | 0.85 | JAK2 (0.76) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL5027435 | 0.84 | JAK2 (0.73) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL5027437 | 0.84 | JAK2 (0.73) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL5032152 | 0.84 | JAK2 (0.74) | JAK2JAK3NTRK1LIMK1LIMK2 | |
| SCHEMBL2578229 | 0.84 | NTRK1 (0.78) | JAK2JAK3NTRK1LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| EP-1853602-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-7622482-B2 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA (SE) | 2009-11-24 | — | — | US | disclosed |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K2 | JAK2 226/4885JAK3 263/4885NTRK1 1107/4885 |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ERBB4, ERBB2, ABL1 | JAK2 61/4885JAK3 32/4885NTRK1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.